Q-omics provides the consensus-scored FBXO44 profile across patient tissues and cancer cell-line models. FBXO44 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, FBXO44 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, FBXO44 protein abundance shows 18,212 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UCEC, COAD, and GBM as cancer lineages where FBXO44 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FBXO44 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FBXO44 survival associations across molecular data types. FBXO44 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FBXO44 RNA expression–survival associations across cancer types. High FBXO44 expression shows unfavorable associations in UCEC and LUSC, but favorable associations in KIRP, MESO, BLCA and LUAD. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for FBXO44 RNA expression.
This table summarizes FBXO44 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 4. The strongest signals are observed in COAD for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for FBXO44. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FBXO44 shows lower tumor expression in KIRP, KIRC and UCEC and higher tumor expression in COAD, HNSC and LIHC. The COAD box plot shows higher FBXO44 RNA expression in tumor versus normal tissue (log2 FC = +1.117, t-test p < 0.001).
This table shows molecular features associated with FBXO44 in patient tissues and cancer cell lines. In patient samples, FBXO44 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, FBXO44 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LIVER and LARGE_INTESTINE.
